Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Research output: Contribution to journalArticle

Abstract

Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

Original languageEnglish (US)
Pages (from-to)520-521
Number of pages2
JournalAsian Journal of Andrology
Volume14
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Active Immunotherapy
Prostatic Neoplasms
Immunotherapy
Vaccines
Monoclonal Antibodies
Safety
Therapeutics
Research

ASJC Scopus subject areas

  • Urology

Cite this

@article{7a77e5bef1f049eda6f92ca51bd53115,
title = "Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer",
abstract = "Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.",
author = "Emmanuel Antonarakis",
year = "2012",
month = "7",
doi = "10.1038/aja.2012.45",
language = "English (US)",
volume = "14",
pages = "520--521",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

AU - Antonarakis, Emmanuel

PY - 2012/7

Y1 - 2012/7

N2 - Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

AB - Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863695808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863695808&partnerID=8YFLogxK

U2 - 10.1038/aja.2012.45

DO - 10.1038/aja.2012.45

M3 - Article

C2 - 22580638

AN - SCOPUS:84863695808

VL - 14

SP - 520

EP - 521

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 4

ER -